Additionally, in 2022, the International Consensus Classification (ICC) for Myeloid Neoplasms and Acute Leukemias introduced an updated framework for myelodysplastic neoplasms that further foregrounds molecular and cytogenetic features (e.g., SF3B1 mutation, isolated del(5q)) [20]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.